NEW YORK (GenomeWeb) – DiaCarta said today that it has completed a Series B funding round, raising a total of $45 million. The second closing was led by Fortune Fountain Capital and included an investment from Good Health Capital.
...and receive Daily News bulletins.
Already have a 360Dx or GenomeWeb account?Login Now.
With the Next Generation Sequencing (NGS), genomes sequencing has been democratized over the last decades with the detection of genomic alterations, thus replacing Sanger sequencing.